Men's Health News

RSS

PARP inhibitors may be effective in men with prostate cancer due to BRCA2 alteration: Researchers

The way prostate cancer develops in men who have an altered 'breast cancer gene' is the same route by which breast cancer develops in women with the same mutation, reveals a study published in PLoS Genetics today (Thursday).

25 Jun 2010

Minnesota AIDS Project awarded federal grant to support HIV prevention services for young gay, bisexual men

The Minnesota AIDS Project is pleased to announce that it has been notified that it will be awarded a federal grant for five years totaling over $1.5 million from the Centers for Disease Control targeting HIV prevention services for young gay and bisexual men in Minnesota. This segment of the community represents the fastest growing population of HIV infections in Minnesota with the total number of new cases in 2009 at the highest level since 1994. The Minnesota AIDS Project Board of Directors is focusing its efforts to reduce these numbers and is committed to using the funds to target these prevention services.

25 Jun 2010

Researchers develop new assay test for bladder cancer

Researchers from the Danish Cancer Society and the Herlev University Hospital of Copenhagen have developed a novel assay to test for multiple tumor markers in bladder cancer.

25 Jun 2010

Palatin announces completion of patient dosing, database lock in bremelanotide study for ED

Palatin Technologies, Inc. today announced the completion of patient dosing and database lock in a double-blind, placebo-controlled, multiple dose, crossover study of bremelanotide, its subcutaneously administered melanocortin agonist for treatment of erectile dysfunction (ED). Palatin expects to report top-line data in the next calendar quarter.

24 Jun 2010

AVIS donates health research project focuses on cancer biomarkers

The greatest research project on cancer biomarkers is to start in the next months. The new scientific research will open new frontiers in the field of prevention of two most relevant cancer: prostate cancer and ovarian cancer. The research project, which also includes an important prevention programme, is named "AVIS donates health" (AVIS is the Italian most important blood donors association) and is supported by Fondazione Abo - Application of biotechnologies in Oncology, Avis, Lilt (Italiana League for the fight against cancer) and by the three scientific societies of gynecologists and urologists.

24 Jun 2010

Female biology screens for the best sperm: Study

A new study has revealed that the female reproductive system is ‘choosy’ when it comes to inferior quality sperm and rejects the ‘advances’ of spermatozoa that are not good enough to create a pregnancy.

23 Jun 2010

Optimum radiation dose on same day as brachytherapy implant can control prostate cancer

Ensuring the optimum radiation dose on the same day as the brachytherapy implant in prostate cancer treatment manages to control the illness in about 95% of the cases. This is the result of research undertaken at the University Hospital of Navarre and published in the latest issue of Brachytherapy, journal of the American Society of Brachytherapy.

23 Jun 2010

Study shows monitoring can be the best treatment for men with prostate cancer of low-risk type

Monitoring can be the best treatment for men with prostate cancer of the low-risk type, according to a study now being published in the Journal of the National Cancer Institute. The lead author is Pär Stattin, a urologist at Umeå University.

23 Jun 2010

Nymox reports positive new results from NX02-0014 follow-up study of NX-1207 for BPH

Nymox Pharmaceutical Corporation is pleased to report positive new results from the 48-60 month follow-up study of patients treated with NX-1207 in Study NX02-0014. The initial study, completed in the U.S. in 2006, reached statistical significance in Intent-to-Treat Primary Efficacy outcomes at 90 days post-treatment with NX-1207 2.5 mg.

23 Jun 2010

Exposure to chlordecone associated to increased risk of prostate cancer: Researchers

In an article to be published on 21 June 2010 in the Journal of Clinical Oncology, researchers from Inserm (Inserm unit 625 - Research Group on Human and Mammalian Reproduction, University of Rennes 1), the CHU (University Hospital Centre) in Pointe - Pitre (urology department, University of the French West Indies and Guiana) and from the Center for Analytical Research and Technology (University of Li-ge, Belgique), show that exposure to chlordecone (also named Kepone), an organochlorine chemical with well defined estrogenic properties used in the French West Indies until 1993, is associated to a significant increased risk of prostate cancer.

23 Jun 2010

OncoGenex initiates Phase 3 Prostate Cancer SATURN Trial

OncoGenex Pharmaceuticals, Inc. announced today the initiation of a Phase 3 registration trial of custirsen sodium (OGX-011/TV-1011), its lead product candidate being developed for the treatment of castrate-resistant prostate cancer (CRPC). This trial, referred to as the Prostate Cancer SATURN Trial, is the first of three Phase 3 trials to be initiated under a global collaboration and license agreement between OncoGenex and Teva Pharmaceutical Industries to develop and commercialize OGX-011/ TV-1011.

21 Jun 2010

Active surveillance sufficient for patients with low-risk prostate cancer

Active surveillance or watchful waiting might be sufficient treatment for patients with prostate cancer that has a low risk of progression, according to a new study published online June 18 in The Journal of the National Cancer Institute.

19 Jun 2010

Data shows younger, unmarried men are least aware of hypertension

Younger, unmarried men around the world are least likely to be aware of hypertension (high blood pressure) and less likely to be receiving treatment. Whereas older women, are most aware of hypertension according to data presented today at the World Congress of Cardiology Scientific Sessions in Beijing, China.

19 Jun 2010

AMLU, OPEIU partner with Ed Randall's Bat for the Cure to raise funds for fight against prostate cancer

The Association of Minor League Umpires and its parent organization, Office and Professional Employees International Union, have partnered with "Ed Randall's Bat for the Cure – Strike Out Prostate Cancer" to raise funds for the fight against prostate cancer. This Father's Day weekend, June 19-20, the minor league umpires open their personal checkbooks and donate 1 cent for every pitch thrown in their Minor League Baseball games.

19 Jun 2010

Most men admitted for heart attack had erectile dysfunction

Seven out of 10 men admitted to hospital for a heart attack (acute ST segment elevation myocardial infarction (STEMI)) had erectile dysfunction (ED) in the six months prior to their admission according to new data presented today at the World Congress of Cardiology (WCC) Scientific Sessions in Beijing, China.

19 Jun 2010

SAHM strongly recommends HPV vaccines for males

On May 28, 2010, the Advisory Committee on Immunization Practices published its guidance for use of the quadrivalent HPV vaccine in males. While noting that the vaccine was approved by the FDA for use in males ages 9 through 26 to reduce their likelihood of acquiring genital warts and that it therefore could be given for this purpose, the statement released by ACIP did not recommend routine HPV vaccination of males.

19 Jun 2010

Research may identify reasons underlying increased risk of AAA in men

Research currently being undertaken at the University of Leicester may identify reasons underlying an increased risk of Abdominal Aortic Aneurysms in men.

19 Jun 2010

FDA approves Jevtana to treat men with prostate cancer

The U.S. Food and Drug Administration today approved Jevtana (cabazitaxel), a chemotherapy drug used in combination with the steroid prednisone to treat men with prostate cancer. Jevtana is the first treatment for advanced, hormone-refractory, prostate cancer that has worsened during or after treatment with docetaxel, a commonly used drug for advanced prostate cancer.

18 Jun 2010

$FDA approves Jevtana in combination with prednisone for metastatic hormone-refractory prostate cancer$

FDA approves Jevtana in combination with prednisone for metastatic hormone-refractory prostate cancer

Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) has granted marketing authorization for Jevtana® (cabazitaxel) Injection in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated with a docetaxel-containing treatment regimen.

18 Jun 2010

Research findings shed light on risk factors, prevention strategies for suicide

Masculine ideals of strength coupled with strong family ties can help men combat depression and overcome thoughts of suicide, according to University of British Columbia research.

17 Jun 2010

Men's Health News

PARP inhibitors may be effective in men with prostate cancer due to BRCA2 alteration: Researchers

Minnesota AIDS Project awarded federal grant to support HIV prevention services for young gay, bisexual men

Researchers develop new assay test for bladder cancer

Palatin announces completion of patient dosing, database lock in bremelanotide study for ED

AVIS donates health research project focuses on cancer biomarkers

Female biology screens for the best sperm: Study

Optimum radiation dose on same day as brachytherapy implant can control prostate cancer

Study shows monitoring can be the best treatment for men with prostate cancer of low-risk type

Nymox reports positive new results from NX02-0014 follow-up study of NX-1207 for BPH

Exposure to chlordecone associated to increased risk of prostate cancer: Researchers

OncoGenex initiates Phase 3 Prostate Cancer SATURN Trial

Active surveillance sufficient for patients with low-risk prostate cancer

Data shows younger, unmarried men are least aware of hypertension

AMLU, OPEIU partner with Ed Randall's Bat for the Cure to raise funds for fight against prostate cancer

Most men admitted for heart attack had erectile dysfunction

SAHM strongly recommends HPV vaccines for males

Research may identify reasons underlying increased risk of AAA in men

FDA approves Jevtana to treat men with prostate cancer

FDA approves Jevtana in combination with prednisone for metastatic hormone-refractory prostate cancer

Research findings shed light on risk factors, prevention strategies for suicide

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News